The stock of Axsome Therapeutics Inc (NASDAQ:AXSM) is a huge mover today! The stock increased 4.95% or $0.39 during the last trading session, hitting $8.27. About 86,802 shares traded hands or 177.68% up from the average. Axsome Therapeutics Inc (NASDAQ:AXSM) has risen 1.42% since February 29, 2016 and is uptrending. It has underperformed by 10.80% the S&P500.
The move comes after 8 months positive chart setup for the $162.28M company. It was reported on Oct, 4 by Barchart.com. We have $13.89 PT which if reached, will make NASDAQ:AXSM worth $110.35 million more.
Analysts await Axsome Therapeutics Inc (NASDAQ:AXSM) to report earnings on November, 8.
Axsome Therapeutics Inc (NASDAQ:AXSM) Ratings Coverage
Out of 2 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Axsome Therapeutics has been the topic of 2 analyst reports since December 14, 2015 according to StockzIntelligence Inc. The stock of Axsome Therapeutics Inc (NASDAQ:AXSM) has “Buy” rating given on Tuesday, December 15 by Cantor Fitzgerald. Ladenburg Thalmann initiated Axsome Therapeutics Inc (NASDAQ:AXSM) on Monday, December 14 with “Buy” rating.
According to Zacks Investment Research, “Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York.”
More notable recent Axsome Therapeutics Inc (NASDAQ:AXSM) news were published by: Benzinga.com which released: “Axsome Therapeutics: Teaching Old Drugs New Tricks” on October 03, 2016, also Quotes.Wsj.com with their article: “News Axsome Therapeutics Inc.AXSM” published on October 30, 2015, Globenewswire.com published: “Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes” on June 27, 2016. More interesting news about Axsome Therapeutics Inc (NASDAQ:AXSM) were released by: Globenewswire.com and their article: “Axsome Therapeutics Announces Closing of Initial Public Offering” published on November 24, 2015 as well as Globenewswire.com‘s news article titled: “Axsome Therapeutics Announces Pricing of Initial Public Offering” with publication date: November 19, 2015.
AXSM Company Profile
Axsome Therapeutics, Inc., incorporated on January 12, 2012, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. The Company’s product candidate portfolio includes two late-stage candidates, AXS 02 and AXS 05, which the Company is developing for multiple indications. The Firm is also developing AXS 06 for the treatment of chronic pain disorders. AXS 06 is in preclinical development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.